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ABSTRACT
Hip fractures account for over one-half the morbidity, mortality, and cost associated with osteoporosis. Fragility of the proximal
femur is the result of rapid and unbalanced bone remodeling events that excavate more bone than they deposit, producing a
porous, thinned, and fragile cortex. We hypothesized that the slowing of remodeling during treatment with denosumab allows
reﬁlling of themany cavities excavated before treatment now opposed by excavation of fewer new resorption cavities. The resulting
net effect is a reduction in cortical porosity and an increase in proximal femur strength. Images were acquired at baseline and
36months usingmultidetector CT in 28women receiving denosumab and 22women receiving placebo in a substudy of FREEDOM, a
randomized, double-blind, placebo-controlled trial involving women with postmenopausal osteoporosis. Porosity was quantiﬁed
using StrAx1.0 software. Strength was estimated using ﬁnite element analysis. At baseline, the higher the serum resorption marker,
CTx, the greater the porosity of the total cortex (r¼ 0.34, p¼ 0.02), and the higher the porosity, the lower the hip strength (r¼ –0.31,
p¼ 0.03). By 36 months, denosumab treatment reduced porosity of the total cortex by 3.6% relative to baseline. Reductions in
porosity relative to placebo at 36 months were 5.3% in total cortex, 7.9% in compact-appearing cortex, 5.6% in outer transitional
zone, and 1.8% in inner transitional zone (all p< 0.01). The improvement in estimated hip integral strength of 7.9% from baseline
(p< 0.0001) was associated with the reduction in total porosity (r¼ –0.41, p¼ 0.03). In summary, denosumab reduced cortical
porosity of the proximal femoral shaft, resulting in increased mineralized matrix volume and improved strength, changes that may
contribute to the reduction in hip and nonvertebral fractures reportedwith denosumab therapy. © 2016 The Authors. Journal of Bone
and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR).
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Introduction
Vertebral fractures have served as hallmarks of osteoporosisfor over 70 years. Indeed, the reduction of vertebral fracture
risk is the primary endpoint in clinical trials despite evidence that
nonvertebral fractures account for over 70% of all fragility
fractures.(1,2) Of these, hip fractures are responsible for
signiﬁcant morbidity, mortality, and cost in the community.(2,3)
The fragility of the proximal femur in advanced age is the
result of two abnormalities in bone remodeling. After meno-
pause, remodeling becomes unbalanced and rapid; more bone
is resorbed than deposited by large numbers of remodeling
units initiated upon the intracortical, endocortical, and trabecu-
lar surfaces.(4) Rapid remodeling upon trabecular surfaces
produces trabecular bone loss, thinning, and perforation of
the trabeculae.
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However, most age-related bone loss is cortical in origin
because approximately 80% of the skeleton is cortical.(5–7)
Cortical bone is eroded by unbalanced and rapid remodeling
upon the endocortical and intracortical surfaces. Of this bone
loss, most is the result of intracortical remodeling initiated upon
canal surfaces.(7) The canals enlarge focally and those traversing
the inner cortex adjacent to the medullary canal enlarge and
eventually coalesce, producing irregularly shaped large pores
when viewed in cross section.(7) Porosity increases throughout
the cortex and cavitation of the inner cortex ‘trabecularizes’ this
region, forming a transitional zone between the increasingly
porous and thinner but still compact-appearing subperiosteal
cortex and the trabecular bone within the medullary canal.(7)
The increase in porosity produces a reciprocal decrease inmatrix
volume and an exponential reduction in bone’s ability to resist
bending.(8,9)
Denosumab, a fully human RANKL monoclonal antibody,
reduces the risk of vertebral, hip, and nonvertebral fractures by
targeting both the imbalance in bone remodeling and the rate
of remodeling.(10) Within hours of subcutaneous administration,
the activity and lifespan of osteoclasts in existing remodeling
units is reduced, aborting further excavation of resorption
cavities, whereas the appearance of new remodeling sites is
virtually abolished due to the inhibition of RANKL-mediated
osteoclastogenesis.(11,12)
By inhibiting existing resorption and most subsequent
remodeling during therapy, denosumab should either slow or
stop any further decline in areal bone mineral density (aBMD).
However, denosumab treatment increases aBMD of the axial
and appendicular skeleton. Studies in nonhuman primate
models suggest that the increase in aBMD is associated with a
reduction in cortical porosity.(13) Studies in human subjects also
demonstrate that denosumab treatment reduces porosity, but
this has only been demonstrated at the distal radius.(14)
We hypothesized that the increase in proximal femoral cortical
thickness, mass, aBMD, and volumetric BMD (vBMD) associated
with denosumab treatment is associated with a reduction in
porosity of the proximal femoral compact-appearing cortex and
the transitional zone, and increases strength estimated in vivo
using ﬁnite element analysis (FEA).(15–19)
Patients and Methods
Participants
Participants were a subset of the FREEDOM trial (ClinicalTrials.
gov number, NCT00089791); the design has been reported.(10) In
brief, this was an international, multicenter, randomized,
double-blind, placebo-controlled study involving 7808 post-
menopausal womenwith osteoporosis. Participants randomized
to the treatment arm (n¼ 3902) received subcutaneous
denosumab (60mg) every 6 months. Those randomized to
the placebo arm (n¼ 3906) received a subcutaneous placebo
injection every 6 months. All subjects received daily calcium and
vitamin D supplements. A subset of subjects was enrolled in a
QCT imaging substudy. Calibration issues and unavailability of
analyzable scans limited the analyses to 58 subjects for the hip
(n¼ 32 denosumab, n¼ 26 placebo). The primary results of this
substudy have been reported.(20) The analyses in this work were
undertaken in the same subset of subjects with QCT scans at
baseline and 36months that were without movement artifact to
allow quantiﬁcation of porosity (n¼ 28 denosumab, n¼ 22
placebo). The study was conducted in accordance with all
country regulations, the Declaration of Helsinki, and the
International Conference on Harmonisation Good Clinical
Practice Guidelines. All subjects provided written informed
consent prior to enrollment.
Quantification of cortical porosity
Cortical porosity was measured, blinded to treatment, in ﬁve
consecutive slices, 0.5mm pixel size, and 0.7mm slice thickness,
distal to the lesser trochanter from CT scans of the proximal
femur. Cortices in this region of interest (ROI) were 4 to 7mm
thick and were captured by 8 to 14 voxels, allowing delineation
of cortical edges despite the 500mm voxel size. This is similar to
HRpQCT measurements at the distal radius where cortices are
1mm thick and the resolution is 100mm; 10 voxels within the
cortex.
Bone was segmented from background and into its compart-
ments using StrAx1.0, a non-threshold-based segmentation
algorithm (StraxCorp Pty Ltd, Melbourne, Australia).(21) The
method automatically and reproducibly segments bone into (1)
the compact-appearing cortex subjacent to periosteum, (2) the
outer transitional zone adjacent to the compact-appearing
cortex containing cortical fragments, (3) the inner transitional
zone adjacent to the medullary canal containing cortical
fragments and trabeculae abutting the cortex, and (4) trabecular
bone of the medullary canal (Fig. 1). In each cortical
compartment, porosity was quantiﬁed by estimating the void
volume fraction of each voxel. This was achieved by quantiﬁca-
tion of the attenuation produced by background (ie, muscle)
and fully mineralized bone matrix, which has a density of
1200mghydroxyapatite (HA)/cm3 and assigned a value of 100%.
Voxels that were completely empty and had an attenuation
equivalent to background were assigned a value of 0%. The
volume fraction of a voxel that is void (ie, porosity) is 100%
minus the mineralized bone matrix fraction.
Once deposited, osteoid is rapidly mineralized to become
‘bone,’ reaching  80% of full mineralization (1200mg HA/cm3)
within a few days. Voxels with attenuation values of  80% are
unlikely to contain a pore or part of a pore, because porosity
results in voxel attenuation values < 80% of the maximum.
Variations in attenuation within 80% to 100% of full mineraliza-
tion are likely to reﬂect heterogeneity in secondary mineraliza-
tion of the matrix, thus these voxels are excluded from the
calculation of porosity. Voxels with attenuation < 80% may
contain a pore or part of a pore.(21)
As we have reported, StrAx1.0 facilitates quantiﬁcation of
porosity in low-resolution CT images even though pores are not
visible to the naked eye.(22,23) The correlations between bone
cross-sectional area measurement made using HRpQCT (Xtre-
meCT; Scanco Medical AG, Br€uttisellen, Switzerland) and clinical
CT, of the same ROI at the subtrochanteric region of the proximal
femur in 11 cadaveric specimens, ranged from r¼ 0.99 (for the
entire bone and for the total cortex) to 0.95 (for the inner
transitional zone) (Fig. 2A). The percentage volume occupied by
pores within those bone regions was identiﬁed by StrAx1.0
regardless of the resolution of the image; the correlation
between porosity measured by HRpQCT and the lower
resolution CT method was 0.94 for total cortical porosity, and
0.93, 0.90, and 0.86 for porosity of the compact-appearing cortex
and outer and inner transitional zones, respectively (Fig. 2B). The
Bland–Altman plot showed that the error (difference between
measurements by CT and HRpQCT scanning) ranged from 0% to
10% depending on the compartment, and agreement between
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both measurements exceeded 90% (Fig. 2C). The in vivo and
ex vivo precision error was < 4%.(21–23)
Measurement of bone resorption, BMD, mass, thickness,
and strength
Morning fasting samples were obtained at baseline in all
subjects for measurement of serum CTx (sCTx), a marker of bone
resorption. Serum CTx was measured with the use of ELISA
(Nordic Bioscience Diagnostics A/S, Herlev, Denmark). DXA scans
were analyzed to assess aBMD at the total hip.(10) QCT scans of
the hip were performed at 120 kV, a pitch of 1, using 170mA,
reconstructed using a 400mm ﬁeld of view, a slice thickness
of  1.25mm, and a medium kernel at baseline.(20) Scans were
analyzed in a blinded-to-treatment manner by a central
laboratory (Synarc Inc., Newark, CA, USA). These scans were
analyzed using Medical Image Analysis Framework (MIAF)
software to assess vBMD of the total hip and compartments.(15)
Additionally, cortical 3D bone thickness maps of the hip were
created from QCT scans, and cortical mass surface density maps
were created.(18) To estimate strength, the QCT images were
calibrated, segmented, and converted into ﬁnite element
models (40,000 elements per model), using cube-shaped,
eight-noded brick elements (1.5mm sided). Femoral strength for
a simulated sideways fall was estimated blinded to treatment.(24)
We report vBMD of the cortical compartment, cortical mass
surface density and thickness, and strength assessed by FEA for
subjects included in the porosity analysis.
Statistical analyses
Quantiﬁcation of the percentage volume of the cortex of the
proximal femur measured immediately below the lesser
trochanter occupied by pores by the StrAx1.0 software included
all subjects with evaluable data at baseline and 36 months.
Pearson correlation coefﬁcients were calculated to assess the
Fig. 1. Cross-section image of proximal femur and its compartments. Segmented computed tomography image obtained at the proximal femur using
StrAx1.0, a non-threshold-based segmentation algorithm, showing the total cortex (the area used for the cortical porosity measurements), consisting of
the three cortical compartments: compact-appearing cortex, outer and inner (red) transitional zones, and trabecular bone area. Porosity was assessed
from QCT slices distal to the lesser trochanter.
Fig. 2. Correlation between (A) cross-sectional areas of the cortical bone measured by HRpQCT and clinical CT, (B) porosities measured by HRpQCT and
clinical CT, and (C) a Bland–Altman plot comparing porosities measured by HRpQCT and clinical CT. There were strong correlations between
measurement techniques (r 0.86 for all bone compartments) and the Bland–Altmanplot showed that the difference betweenmeasurements by CT and
HRpQCT ranged from 0% to 10% depending on the compartment, and thus the agreement between both measurements exceeded 90%. Each point
represents one anatomic specimen.
Journal of Bone and Mineral Research DENOSUMAB REDUCES PROXIMAL FEMORAL POROSITY 1829
association between porosity and other bone measurements at
baseline and change in total porosity and strength at 36months.
Baseline and 36 months porosity results were reported as
mean SD. Least-squares mean with two-sided 95% CI and p
values were obtained using an ANCOVA model, adjusting for
treatment and baseline value to estimate absolute or percent-
age change in cortical porosity, aBMD, vBMD, thickness, mass,
and strength from baseline to 36 months within treatment
group and the difference between groups at 36 months.
Results
Baseline measurements
Patient demographics, sCTx, and bone traits were comparable in
the two groups at baseline (Table 1). Women with higher sCTx
had higher total cortex porosity (r¼ 0.34, p¼ 0.02). Women with
higher total cortex porosity had lower aBMD (r¼ –0.37, p< 0.01),
lower total cortical vBMD (r¼ –0.46, p< 0.01), thinner cortices
(r¼ –0.33, p¼ 0.02), lower cortical mass (r¼ –0.39, p< 0.01),
and lower estimated integral strength (r¼ –0.31, p¼ 0.03)
(Fig. 3A–F).
Changes during follow-up
In the denosumab group, porosity of all cortical regions
decreased relative to baseline (Table 2). The percentage change
from baseline at 36 months was –3.6% (95% CI, –5.2% to –1.9%)
for the total cortex, –6.7% (95% CI, –9.7% to –3.7%) for the
compact-appearing cortex, –5.9% (95% CI, 8.0% to –3.8%) for
the outer transitional zone, and –1.1% (95% CI, –1.7% to –0.5%)
for the inner transitional zone (all p< 0.01) (Fig. 4). In the placebo
group, porosity remained unchanged relative to baseline, with
percentage differences at 36 months being 1.7% (95% CI, –0.1%
to 3.6%), 1.2% (95% CI, –2.2% to 4.6%), –0.3% (95% CI, –2.7% to
2.0%), and 0.6% (95% CI, 0.0% to 1.3%) at the respective regions
(Fig. 4).
At 36 months, signiﬁcant differences in the denosumab group
relative to placebo were observed for porosity in all cortical
regions (allp< 0.001) (Table 2), aswell as the total hip aBMD (5.1%
versus –0.7%), total cortical vBMD (5.2% versus 0.5%), cortical
thickness (2.1% versus –1.3%), cortical mass (4.2% versus –0.9%),
and FEA integral strength (7.9% versus –5.0%) (all p< 0.0001).
In the denosumab group, the reduction in porosity was
associated with an increase in estimated integral strength for
total cortex (r¼ –0.41, p¼ 0.03) (Fig. 5), compact-appearing
cortex (r¼0.42, p¼ 0.02), and outer transitional zone (r¼ –
0.52, p< 0.01).
Discussion
We report that, prior to treatment, higher sCTx was associated
with higher cortical porosity in the proximal femoral shaft, and
that higher porosity was associated with lower estimated bone
strength. Denosumab treatment reduced porosity of the total
cortex, its compact-appearing region, and outer transitional
zone. The reduction in porosity correlated with an increase in
estimated strength.
Antiresorptive drugs reduce the volume of bone resorbed by
osteoclasts of each remodeling unit so that the resorptive
cavities become smaller.(25) However, the main mechanism
responsible for a reduction in the rate of bone loss and slowing
of structural deterioration is the reduction in rate of remodel-
ing.(26,27) Previous studies have reported that denosumab
treatment increased aBMD, vBMD, cortical thickness, mass,
and estimated bone strength relative to previous treatment as
well as controls.(15,18,24) Our ﬁndings conﬁrm these observations
and show that denosumab treatment reduces porosity at the
proximal femoral shaft, as it does at the distal radius,(14) in
postmenopausal women.
Several mechanisms are likely to account for the reduction in
porosity, the increase in cortical thickness, mass, aBMD, and
vBMD associated with denosumab treatment. Prior to treat-
ment, remodeling is rapid. For each of the many remodeling or
basic multicellular units (BMUs), the reﬁlling phase of remodel-
ing is delayed by about a week by a reversal or resting phase and
then reﬁlling proceeds slowly for about 3 months.(27–29)
When denosumab treatment is initiated, BMUs excavating
cavities prior to treatment stop resorbing, are aborted, or enter
their reversal and then reﬁlling phase. Concurrently, denosumab
rapidly abolishes the birth of new resorption sites, so that the
result of reﬁlling of many cavities excavated before treatment
plus the birth of very few new cavities is a net decrease in
porosity. Reﬁlling or partial reﬁlling of cavities excavated upon
the Haversian canals and the endocortical surface increases
mineralized matrix cortical volume and partly restores cortical
thickness focally, so that there is a net increase in the volume of
mineralized matrix enveloped by the periosteal and endocort-
ical surfaces and a reciprocal decrease in the void volume.
Secondary mineralization of matrix deposited in cavities
Table 1. Baseline Characteristics
Placebo
(n¼ 22)a
Denosumab
(n¼ 28)a
Age (years) 73.8 6.3 73.0 4.7
Body mass index (kg/m2) 24.9 4.2 26.5 5.3
Total hip
T-score 2.0 0.7 1.6 0.9
DXA aBMD (g/cm2) 0.7 0.1 0.7 0.1
MIAF cortical vBMD (mg/cm3) 514 54 533 58
Proximal femur cortical mass
surface density (mg/cm2)b
141 18 145 19
Proximal femur cortical thickness
(mm)b
1.2 0.2 1.3 0.2
Cortical volume occupied by pores (%)c
Total 39.5 7.6 40.9 11.1
Compact-appearing cortex 28.4 6.8 28.7 11.1
Outer transitional zone 37.5 5.4 36.7 8.8
Inner transitional zone 71.4 3.8 72.0 3.6
FEA hip integral strength (N) 2228 592 2460 640
sCTx (ng/mL), median (IQR) 0.44
(0.37–0.58)
0.47
(0.34–0.69)
Data are mean SD unless otherwise indicated. n¼number of
subjects with available hip porosity data at baseline and 36 months.
aBMD¼ areal BMD; MIAF¼Medical Image Analysis Framework;
vBMD¼ volumetric BMD; FEA¼ ﬁnite element analysis; sCTx¼ serum
CTx; IQR¼ interquartile range; N¼Newtons.
aBetween-group t test, p> 0.05 for all characteristics.
bn¼ 21, placebo.
cCortical volume is the volume enveloped by the periosteal and
endocortical surface. Of this volume, 30% to 40% is void volume formed
by canals traversing the cortex. In cross sections of cortex, these canals
form most of the “porosity.” Porosity was assessed below the lesser
trochanter.
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excavated prior to treatment and matrix no longer resorbed
(because remodeling is suppressed) further contributes to
increases in cortical vBMD.(18)
After about 12 months, a new steady state is established with
remodeling proceeding slowly provided denosumab adminis-
tration continues. BMD continues to increase, but more slowly
for two reasons. First, secondary mineralization of recently
formed osteons and osteons formed months to years earlier
continues, because it can take several years to reach comple-
tion.(30) Second, studies in cynomolgus monkeys treated with
denosumab suggest that, in the face of markedly reduced
remodeling, modeling-based bone formation no longer ob-
scured by high remodeling may proceed upon quiescent
intracortical and endocortical surface of loaded cortical regions
of the proximal femur.(13,31) This bone formation is independent
of bone resorption and is unlikely to be a direct effect of
denosumab. We propose that prior to treatment, high
remodeling obscures, or may remove, bone deposited by
continued modeling-based bone formation throughout life.
When no longer opposed by remodeling, such as achieved by
denosumab administration, continued modeling could result in
a prolonged net gain in bone matrix volume. This partial
restoration of microstructure and increase in matrix mass may
further increase bone strength and contribute to reductions in
fracture rate.
This study is one of the ﬁrst to report of noninvasive in vivo
human quantiﬁcation of porosity at the proximal femur,
assessed at the shaft immediately distal to the lesser trochanter,
using a clinically available CT technology. Although reductions
in porosity of the distal radius and tibia in response to
antiresorptive therapy have been reported,(14,32) these are
based on the use of HRpQCT, a technique available in only a few
Fig. 3. Association between baseline proximal femoral total cortical porosity assessed distal to the lesser trochanter and (A) sCTx, (B) aBMD, (C) vBMD,
(D) cortical thickness, (E) cortical mass surface density, and (F) strength. At baseline, (A) women with higher sCTx had higher total cortex porosity; (B)
women with higher total cortex porosity had lower aBMD, (C) lower total cortical vBMD, (D) thinner cortices, (E) lower cortical mass, and (F) lower
estimated integral strength. Regression line is based on both treatment groups combined. aBMD¼ areal BMD; MIAF¼Medical Image Analysis
Framework; sCTx¼ serum CTx; vBMD¼ volumetric BMD.
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specialized centers worldwide. Additionally, these sites of
fragility fracture are of less relevance in terms of morbidity
and mortality than the proximal femur.
This study has several limitations. The small sample size
precludes a robust assessment of the association between
the changes in porosity, bone strength, or fracture. Because
measurements of porosity were made at the shaft below the
lesser trochanter, inferences concerning associations between
changes in porosity at other regions, such as at the femoral neck,
require further study. The study also cannot address to what
extent the fracture risk reduction documented in FREEDOM is
related to the reduction in porosity. Nevertheless, the reduction
in porosity correlated with the improvement in estimated bone
strength in this subset of individuals and, despite the low
numbers of subjects studied, signiﬁcant relations were
documented. Larger sample sizes are needed to conﬁrm these
associations. The StrAx technique is very sensitive to image
quality, thus image quality without motion is essential for
accurate quantiﬁcation of porosity. In addition, we assumed,
consistent with previous research,(21) that the area occupied
only by mineralized matrix free of pores has a matrix mineral
density of  80% of the maximum mineral density achievable.
We cannot exclude the possibility of a small pore contributing
and introducing a small error.(33) Finally, because muscle is used
for calibration, fatty inﬁltration may introduce small errors in the
results.
Image resolution of the techniques used in this study and
differences in secondary mineralization may inﬂuence quantiﬁ-
cation of porosity. However, this was minimized by excluding
voxels with attenuation between 80% and 100% of the
Table 2. Proximal Femoral Porosity (%) Assessed Distal to the Lesser Trochanter at Baseline, 36Months, Absolute Change From Baseline
by Treatment Group
Placebo (n¼ 22) Denosumab (n¼ 28)
Denosumab
versus
placebo
Baseline 36 Months
Absolute
change
from
baseline pa Baseline 36 Months
Absolute
change
from
baseline pa pb
Total cortex 39.5 7.6 40.1 7.4 0.6 0.08 40.9 11.1 39.5 11.1 1.4 <0.0001 <0.0001
Compact-appearing cortex 28.4 6.8 28.7 6.9 0.3 0.46 28.7 11.1 27.0 11.2 1.7 <0.0001 0.0007
Outer transitional zone 37.5 5.4 37.4 5.7 0.1 0.80 36.7 8.8 34.7 9.3 2.0 <0.0001 0.0009
Inner transitional zone 71.3 3.8 71.8 3.5 0.4 0.06 72.0 3.6 71.2 3.7 0.8 0.0002 0.0002
Data are mean SD for baseline and 36 months; absolute change from baseline data are least-squares means based on ANCOVA model adjusting for
treatment and baseline value.
ap value for 36 months versus baseline within each treatment group.
bp value for denosumab versus placebo at 36 months (denosumab –placebo).
Fig. 4. Percentage change from baseline at 36 months in proximal femoral total cortical porosity assessed distal to the lesser trochanter in response to
denosumab or placebo treatment. In the denosumab group, porosity decreased in all regions relative to baseline at 36months. The reduction in porosity
of the total cortex was mainly attributable to decreases in porosity of the compact-appearing cortex and outer transitional zone. Porosity remained
unchanged relative to baseline in the placebo group. The differences in porosity in the denosumab group relative to placebo at 36 months were
signiﬁcant in all regions (all p< 0.01). n¼number of subjects with available data at baseline and 36 months. Data are least-squares means and 95% CIs.
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maximum mineralization produced by 1200mg HA/cm3 be-
cause differences in attenuation by these voxels weremost likely
to be due to differences in mineralization, not porosity. Porosity,
if present, would reduce attenuation below 80% of the
maximum.(21) Despite the image resolution utilized, this analysis
conﬁrmed earlier work reporting that denosumab treatment
reduced porosity of the cortex of the distal radius and distal tibia
of postmenopausal women quantiﬁed using higher-resolution
HRpQCT images, and reduced porosity of the cortex of the iliac
crest of cynomolgus monkeys using histomorphometry.(13,14)
Nevertheless, these changes still may be underestimates
because smaller pores may not be identiﬁed at a voxel size
ranging from 500 to 700mm.
In summary, we conﬁrm and extend reports of ex vivo studies
in animal models, and reports in human subjects documenting a
reduction of cortical porosity associated with denosumab
therapy. Quantiﬁcation of cortical porosity of the hip provides
ameans of assessing fracture risk and the effects of treatment on
this important determinant of bone strength. The beneﬁts of
denosumab treatment in reducing porosity at this location are
relevant to our understanding of the structural basis of the
reduced nonvertebral and hip fracture risk observed in clinical
trials.
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